当前位置:
X-MOL 学术
›
Mol. Omics
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma
Molecular Omics ( IF 2.9 ) Pub Date : 2019-01-07 , DOI: 10.1039/c8mo00193f Giao N. Lê 1, 2, 3, 4, 5 , Jonathan Bones 1, 2, 3 , Mark Coyne 3, 6, 7, 8 , Despina Bazou 3, 6, 7, 8 , Paul Dowling 3, 9, 10, 11 , Peter O’Gorman 3, 6, 7, 8 , Anne-Marie Larkin 3, 4, 5, 12
Molecular Omics ( IF 2.9 ) Pub Date : 2019-01-07 , DOI: 10.1039/c8mo00193f Giao N. Lê 1, 2, 3, 4, 5 , Jonathan Bones 1, 2, 3 , Mark Coyne 3, 6, 7, 8 , Despina Bazou 3, 6, 7, 8 , Paul Dowling 3, 9, 10, 11 , Peter O’Gorman 3, 6, 7, 8 , Anne-Marie Larkin 3, 4, 5, 12
Affiliation
Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal heterogeneity. Over the years, many clinical trials and researches have led to the development of effective myeloma treatments, resulting in survival prolongation. Molecular prognostic markers for risk-stratification to predict survival, and predictive markers for treatment response are being extensively explored. This review discusses the current risk-adaptive strategies based on genetic and molecular risk signatures that are in practice to predict survival and describes the future prognostic and predictive biomarkers across the fields of genomics, proteomics, and glycomics in myeloma. Gene expression profiling and next generation sequencing are coming to the forefront of risk-stratification and therapeutic-response prediction. Similarly, proteomic and glycomic-based platforms are gaining momentum in biomarker discovery to predict drug resistance and disease progression.
中文翻译:
当前和未来的生物标志物,用于多发性骨髓瘤的风险分层和个性化治疗
多发性骨髓瘤是骨髓中浆细胞的一种不可治愈的恶性肿瘤,由于克隆异质性而具有复杂的发病机理。多年来,许多临床试验和研究已导致开发有效的骨髓瘤治疗方法,从而延长了生存期。目前正在广泛探索用于风险分层以预测生存的分子预后标志物和用于治疗反应的预测性标志物。这篇综述讨论了基于遗传和分子风险特征的当前风险适应策略,这些策略在实践中可预测生存,并描述了骨髓瘤的基因组学,蛋白质组学和糖组学领域的未来预后和预测性生物标志物。基因表达谱分析和下一代测序已成为风险分层和治疗反应预测的最前沿。同样,蛋白质组学和基于糖组学的平台正在生物标记物发现中获得发展势头,以预测耐药性和疾病进展。
更新日期:2019-02-13
中文翻译:
当前和未来的生物标志物,用于多发性骨髓瘤的风险分层和个性化治疗
多发性骨髓瘤是骨髓中浆细胞的一种不可治愈的恶性肿瘤,由于克隆异质性而具有复杂的发病机理。多年来,许多临床试验和研究已导致开发有效的骨髓瘤治疗方法,从而延长了生存期。目前正在广泛探索用于风险分层以预测生存的分子预后标志物和用于治疗反应的预测性标志物。这篇综述讨论了基于遗传和分子风险特征的当前风险适应策略,这些策略在实践中可预测生存,并描述了骨髓瘤的基因组学,蛋白质组学和糖组学领域的未来预后和预测性生物标志物。基因表达谱分析和下一代测序已成为风险分层和治疗反应预测的最前沿。同样,蛋白质组学和基于糖组学的平台正在生物标记物发现中获得发展势头,以预测耐药性和疾病进展。